Identification of Predictive Biomarkers to Prevent Pneumonitis in Patients with Non-Small Cell Lung Cancer Who are Receiving Immunotherapy (Phase II)

Lung Cancer
Active Trial
Ajay Sheshadri, MD
The University of Texas MD Anderson Cancer Center

Summary:

Dr. Linehan’s trial is examining the use of a dual immunotherapy approach in combination with standard chemotherapy to treat inoperable and locally advanced pancreatic ductal cancer (PDAC). The dual immunotherapy drugs, nivolumab and pepinemab, will activate the immune system to fight against the pancreatic tumors thereby enhancing the effectiveness of the chemotherapy folfirinox in targeting and eradicating the tumor cells. If successful, this trial will result in a new, more effective treatment approach for patients diagnosed with PDAC.